Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
Condition: Basal Cell Carcinoma Interventions: Drug: LDE225B; Drug: Vehicle Sponsor: Novartis Pharmaceuticals Terminated - verified February 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 6, 2010 Category: Research Source Type: clinical trials
